

## Quarterly Activity Report and Appendix 4C

### Key Metrics for 2Q 2022

ACTIVATED LIVES	CONSULTATIONS	SECONDARY CARE JOURNEYS	REPEAT PATIENTS
<b>756k</b>	<b>151k</b>	<b>7k</b>	<b>47k</b>
<b>+35%</b> on pcp	<b>+69%</b> on pcp	<b>+117%</b> on pcp	<b>+38%</b> on pcp

Doctor Care Anywhere Group PLC (ASX:DOC, "Doctor Care Anywhere" or "the Company") is pleased to provide an update on trading for the quarter ended 30 June 2022 ("2Q 2022")<sup>1</sup>.

The Company will provide a full update for the half year ended 30 June 2022 when its H1 results are published in mid-August 2022.

### Cash Position: Progress to Profitability and Net Cash Generation

Cash receipts from customers increased by 12% (£0.9 million : A\$1.7 million) to £8.7 million (A\$16.4 million). This increase was predominantly driven by revenue growth in 1Q 2022, which due to customer payment terms was paid in 2Q 2022.

Net operating cash outflows decreased by 35% (£1.9 million : A\$3.6 million) to £3.6 million (A\$6.8 million). This decrease was driven by the increase in cash receipts from customers (as referenced above), driving productivity in the business to lower costs and working capital initiatives.

Net investing cash outflows for the quarter were £0.9 million, an increase of £0.2 million on the prior quarter. This was driven by the business continuing to invest in its technology platform.

Net cash outflows from financing activities for the quarter were £0.1 million. Net cash flows from financing activities were positive in the prior quarter due to the funds received from a Placement and Retail Security Purchase Plan completed during that quarter.

The Company exited the quarter with £12.4 million (A\$23.4 million) of cash on hand as at 30 June 2022.

### Operational Performance

#### Operational KPIs

	Actual	% increase / (decrease) on	% increase / (decrease) on
	2Q 2022 000's	2Q 2021 (PCP)	1Q 2022 (QoQ)
Eligible Lives <sup>2</sup> at Period End	2,525.8	7.2%	(1.6%)
Activated Lives <sup>3</sup> at Period End	756.3	35.4%	2.9%
Consultations <sup>4</sup> by Period	151.1	69.0%	(0.5%)

<sup>1</sup> This Quarterly Activity Report and Appendix 4C is prepared in GBP in accordance with International Financial Reporting Standards in conformity with the requirements of the Companies Act 2006 (UK). All figures expressed in Australian Dollars ("A\$") have been converted from British Pounds Sterling at an exchange rate of AUD:GBP 1:0.53.

<sup>2</sup> **Eligible Lives** represents the total number of people who have an entitlement to use DOC's services.

<sup>3</sup> **Activated Lives** represents the total number of people who "sign up" for DOC's service and enter their personal details.

<sup>4</sup> **Consultations** are the number of GP, Psychiatrist and Psychologist consultations delivered to patients over the period.

### Commentary


Eligible Lives at the end of 2Q 2022 were 2.5 million, up 7% on the pcp. Growth in Eligible Lives was driven by increased penetration of the Company’s services across existing channel partners.

At the end of 2Q 2022, Activated Lives were 756,300, up 35% on the pcp. Growth in Activated Lives was driven by marketing and engagement activities across the Company’s expanded pool of Eligible Lives.

Consultation volumes continued to grow year-on-year, with 151,100 consultations delivered across 2Q 2022, up 69% on pcp. Growth in consultation volumes was driven by:

- a 38% pcp uplift in new patients to 47,000; and
- improved uptake in the Company’s secondary care pathway (referral for diagnostic tests and specialist review of results), with 7,200 patients completing the pathway; up 117% on pcp.

### Consultations by Quarter (000’s)



Quarter-on-quarter consultation volumes were materially consistent. As referenced in the Company’s trading update for 1Q 2022, this was anticipated due to the concentration in 2Q of UK public holidays impacting both patient demand and clinician supply.

Returning patients represented 69% of all consultations in the quarter, up from 67% in the prior quarter and 62% in the pcp, demonstrating patient satisfaction with the service.

### Other

As required by ASX Listing Rule 4.7C.3, the Company discloses that payments to related parties in the period totalled £0.26 million, representing payment of Director Fees to Non-Executive Directors and salaries to Executive Directors (including pension and payroll tax payments), an increase of £0.08 million on the prior quarter. This increase was driven by a one-off payment to the retiring Chairman relating to his contractual entitlements.

- ENDS -

This ASX announcement has been authorised for release by the Board of Directors.

**About Doctor Care Anywhere:**

*Doctor Care Anywhere Group PLC is the UK's largest private provider of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally-enabled telehealth services on its proprietary platform. It is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways on its proprietary platform. Doctor Care Anywhere utilises its relationships with health insurers, healthcare providers and corporate customers to connect with patients to deliver a range of telehealth services.*

**Forward looking statements:**

*This announcement contains forward-looking statements which are statements that may be identified by words such as "may", "will", "would", "should", "could", "believes", "estimates", "expects", "intends", "plans", "anticipates", "predicts", "outlook", "forecasts", "guidance" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this announcement, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, and the directors and management of the Company. The Company cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.*

**Further Information:**

**Simon Hinsley**

NWR Communications – Investor Relations  
+61 401 809 653  
[simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)

**Dan Curran**

Chief Financial Officer and Company  
Secretary  
[company.secretary@doctorcareanywhere.com](mailto:company.secretary@doctorcareanywhere.com)

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

<b>Name of entity</b>		
Doctor Care Anywhere Group PLC		
<b>ARBN</b>		<b>Quarter ended ("current quarter")</b>
645 163 873		30 June 2022
<b>Consolidated statement of cash flows</b>	<b>Current quarter £'000</b>	<b>Year to date (6 months) £'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	8,731	16,568
1.2 Payments for		
(a) research and development	(1,860)	(3,000)
(b) product manufacturing and operating costs	(5,557)	(11,822)
(c) advertising and marketing	(436)	(783)
(d) leased assets	-	-
(e) staff costs	(2,989)	(6,564)
(f) administration and corporate costs	(1,681)	(4,017)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(1)	(2)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	267
1.8 Other (provide details if material)	234	283
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(3,559)</b>	<b>(9,070)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(12)	(78)
(d) investments	-	-
(e) intellectual property	(842)	(1,515)

<b>Consolidated statement of cash flows</b>		<b>Current quarter £'000</b>	<b>Year to date (6 months) £'000</b>
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received	-	-
2.5	Other	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(855)</b>	<b>(1,593)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	6,408
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(56)	(339)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(78)	(91)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(134)</b>	<b>5,978</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	16,955	17,068
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,559)	(9,070)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(855)	(1,593)

<b>Consolidated statement of cash flows</b>		<b>Current quarter £'000</b>	<b>Year to date (6 months) £'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(134)	5,978
4.5	Effect of movement in exchange rates on cash held	(7)	18
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>12,400</b>	<b>12,400</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter £'000</b>	<b>Previous quarter £'000</b>
5.1	Bank balances	12,400	16,955
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>12,400</b>	<b>16,955</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter £'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	258
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

<b>7. Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end £'000</b>	<b>Amount drawn at quarter end £'000</b>
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
<b>7.4 Total financing facilities</b>	-	-
<b>7.5 Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
n/a		

<b>8. Estimated cash available for future operating activities</b>	<b>£'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(3,559)
8.2 Cash and cash equivalents at quarter end (item 4.6)	12,400
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	<b>12,400</b>
<b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	<b>3</b>
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: n/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: n/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: n/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 July 2022

Authorised by: Board of Directors

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.